Arecibo, PR

Arecibo 00612

0 studies enrolling now · 2 studies all time

What they study most

BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD)

Studies at this site

• A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME — Running, not enrolling
• A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration — Running, not enrolling